Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313543906> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2313543906 endingPage "A216" @default.
- W2313543906 startingPage "A216.1" @default.
- W2313543906 abstract "<h3>Background</h3> The oncology pharmacist was consulted about the neoadjuvant carboplatin-based chemotherapy regimen for a 59-year-old woman with triple negative stage IIA breast cancer and stage 4 chronic kidney disease. She was undergoing haemodialysis three times a week, on a Tuesday-Thursday-Saturday schedule. The chemotherapy regimen was docetaxel 75 mg/m² IV D1, carboplatin AUC 5 IV D1, Q21D, 6 cycles. The major dose-limiting toxicity of carboplatin is myelosuppression, especially thrombocytopenia. As carboplatin is eliminated mainly through the kidneys, dosage adjustment and timing is required for patients with impaired renal function to prevent severe hematologic toxicity. Carboplatin is removed by haemodialysis. <h3>Purpose</h3> To examine the tolerability and safety of carboplatin-based chemotherapy and the applicability of the Calvert formula in a haemodialysis patient with localised breast cancer. <h3>Materials and Methods</h3> We reviewed the literature on the pharmacokinetics, efficacy, tolerability and dosage adjustment of carboplatin. In patients on chronic haemodialysis, the issue is how to evaluate the glomerular filtration rate (GFR) in the Calvert formula. We planned the administration of chemotherapy on a non-dialysis day and the following haemodialysis session to occur 24 hours afterwards. The GFR value was assumed to be 0 mL/min and the carboplatin dose calculated was 125 mg. <h3>Results</h3> The first two chemotherapy cycles were found to be safe and well tolerated. Neither neutropenia nor thrombocytopenia occurred. After the first cycle, absolute neutrophil nadir count was 5.51 10e-3/mcL and platelet nadir count was 238 10e-3/mcL. Neither allergic or hypersensitivity reactions nor delayed nausea or vomiting occurred. CTCAE grade 3 diarrhoea was controlled with loperamide. Furthermore, a significant reduction in the tumour size was attained. <h3>Conclusions </h3> Dosage adjustment and timing of carboplatin-based chemotherapy can result in a safe and well-tolerated preoperative treatment option in a haemodialysis patient with localised breast cancer. No conflict of interest." @default.
- W2313543906 created "2016-06-24" @default.
- W2313543906 creator A5002814132 @default.
- W2313543906 creator A5010410920 @default.
- W2313543906 creator A5010910977 @default.
- W2313543906 creator A5021653484 @default.
- W2313543906 creator A5042956706 @default.
- W2313543906 creator A5083767503 @default.
- W2313543906 date "2013-03-01" @default.
- W2313543906 modified "2023-10-18" @default.
- W2313543906 title "CPC-141 Tolerability and Safety of Carboplatin-Based Chemotherapy in a Hemodialysis Patient with Breast Cancer" @default.
- W2313543906 doi "https://doi.org/10.1136/ejhpharm-2013-000276.598" @default.
- W2313543906 hasPublicationYear "2013" @default.
- W2313543906 type Work @default.
- W2313543906 sameAs 2313543906 @default.
- W2313543906 citedByCount "0" @default.
- W2313543906 crossrefType "journal-article" @default.
- W2313543906 hasAuthorship W2313543906A5002814132 @default.
- W2313543906 hasAuthorship W2313543906A5010410920 @default.
- W2313543906 hasAuthorship W2313543906A5010910977 @default.
- W2313543906 hasAuthorship W2313543906A5021653484 @default.
- W2313543906 hasAuthorship W2313543906A5042956706 @default.
- W2313543906 hasAuthorship W2313543906A5083767503 @default.
- W2313543906 hasBestOaLocation W23135439061 @default.
- W2313543906 hasConcept C121608353 @default.
- W2313543906 hasConcept C126322002 @default.
- W2313543906 hasConcept C126894567 @default.
- W2313543906 hasConcept C143998085 @default.
- W2313543906 hasConcept C197934379 @default.
- W2313543906 hasConcept C2776694085 @default.
- W2313543906 hasConcept C2778239845 @default.
- W2313543906 hasConcept C2778336483 @default.
- W2313543906 hasConcept C2778375690 @default.
- W2313543906 hasConcept C2781413609 @default.
- W2313543906 hasConcept C2781451048 @default.
- W2313543906 hasConcept C530470458 @default.
- W2313543906 hasConcept C71924100 @default.
- W2313543906 hasConceptScore W2313543906C121608353 @default.
- W2313543906 hasConceptScore W2313543906C126322002 @default.
- W2313543906 hasConceptScore W2313543906C126894567 @default.
- W2313543906 hasConceptScore W2313543906C143998085 @default.
- W2313543906 hasConceptScore W2313543906C197934379 @default.
- W2313543906 hasConceptScore W2313543906C2776694085 @default.
- W2313543906 hasConceptScore W2313543906C2778239845 @default.
- W2313543906 hasConceptScore W2313543906C2778336483 @default.
- W2313543906 hasConceptScore W2313543906C2778375690 @default.
- W2313543906 hasConceptScore W2313543906C2781413609 @default.
- W2313543906 hasConceptScore W2313543906C2781451048 @default.
- W2313543906 hasConceptScore W2313543906C530470458 @default.
- W2313543906 hasConceptScore W2313543906C71924100 @default.
- W2313543906 hasIssue "Suppl 1" @default.
- W2313543906 hasLocation W23135439061 @default.
- W2313543906 hasOpenAccess W2313543906 @default.
- W2313543906 hasPrimaryLocation W23135439061 @default.
- W2313543906 hasRelatedWork W1969833561 @default.
- W2313543906 hasRelatedWork W1975832547 @default.
- W2313543906 hasRelatedWork W2022084568 @default.
- W2313543906 hasRelatedWork W2346904363 @default.
- W2313543906 hasRelatedWork W2383272827 @default.
- W2313543906 hasRelatedWork W2388730008 @default.
- W2313543906 hasRelatedWork W3104230093 @default.
- W2313543906 hasRelatedWork W3161469540 @default.
- W2313543906 hasRelatedWork W4210351854 @default.
- W2313543906 hasRelatedWork W4362596311 @default.
- W2313543906 hasVolume "20" @default.
- W2313543906 isParatext "false" @default.
- W2313543906 isRetracted "false" @default.
- W2313543906 magId "2313543906" @default.
- W2313543906 workType "article" @default.